When is HLA‑B27 (human leukocyte antigen B27) testing indicated?

When to Get HLA-B27 Testing

Order HLA-B27 testing when evaluating patients with suspected axial or peripheral spondyloarthritis who have chronic back pain (>3 months duration) starting before age 45, or when evaluating patients with acute anterior uveitis. 1

Clinical Scenarios for HLA-B27 Testing

Axial Spondyloarthritis Evaluation

Test HLA-B27 in patients with:

• Back pain lasting >3 months with onset before age 45 years
• At least 3-4 of the following inflammatory features:
  • Back pain beginning before age 35
  • Nocturnal awakening with back pain requiring movement for relief
  • Buttock pain
  • Improvement with movement or within 48 hours of NSAID use
  • First-degree family member with spondyloarthritis
  • Current or previous arthritis, enthesitis, or psoriasis 1

The most recent ASAS 2024 guidelines emphasize that HLA-B27 status should be communicated when requesting imaging examinations for suspected axial spondyloarthritis, as it helps establish pretest probability and guides radiological interpretation 2. This reflects the test's role as part of the diagnostic workup rather than a standalone screening tool.

Peripheral Spondyloarthritis

HLA-B27 testing increases diagnostic likelihood when positive in patients presenting with peripheral arthritis patterns suggestive of spondyloarthritis 1. Test when evaluating unexplained peripheral arthritis, particularly with features like:

• Asymmetric oligoarthritis
• Lower extremity predominance
• Associated enthesitis
• Extra-articular manifestations

Acute Anterior Uveitis

Order HLA-B27 in all patients with acute anterior uveitis, as ophthalmology demonstrates the highest positive test rate (15.4%) among specialties ordering this test 3. HLA-B27-positive AAU represents the most common form of noninfectious intraocular inflammation and carries significant risk for undiagnosed systemic spondyloarthritis—up to 40% have underlying disease 4.

Critical Caveats

What HLA-B27 Does NOT Do

A negative HLA-B27 test does NOT rule out spondyloarthritis 1. This is a crucial pitfall—axial spondyloarthritis occurs equally in men and women and can occur in HLA-B27-negative individuals. The disease cannot be excluded based on laboratory results alone.

Do not use HLA-B27 as a screening test in asymptomatic populations or patients with nonspecific symptoms 5. The test provides probability information only when applied to appropriate clinical contexts with sufficient pretest probability.

Avoid Inappropriate Co-Testing

Recent data shows that 69.3% of HLA-B27 tests are inappropriately ordered concurrently with ANA, RF, or anti-CCP antibodies 3. This reflects confusion about disease mechanisms—spondyloarthritis is seronegative by definition. Order HLA-B27 when clinical features suggest spondyloarthritis, not as part of a "rheumatology panel."

Interpreting Results

Positive HLA-B27

• Increases likelihood of spondyloarthritis diagnosis when clinical features are present
• Lowers the threshold for rheumatology referral (refer with ≥3 clinical criteria instead of ≥4) 1
• Does NOT confirm diagnosis—requires clinical and imaging correlation
• Prompts evaluation for systemic manifestations (uveitis, inflammatory bowel disease, psoriasis)

Negative HLA-B27

• Does NOT exclude spondyloarthritis
• Proceed with imaging (radiography, then MRI if needed) when clinical suspicion remains high 1
• Continue evaluation based on clinical features and inflammatory markers

Practical Algorithm

1. Patient presents with chronic back pain (>3 months, onset <45 years)

   • Count inflammatory features (see list above)
   • If ≥4 features: Refer to rheumatology AND order HLA-B27
   • If 3 features: Order HLA-B27 first
     • If positive: Refer to rheumatology
     • If negative: Consider imaging if high clinical suspicion persists

2. Patient presents with acute anterior uveitis

   • Order HLA-B27 testing
   • Screen for back pain, arthritis, enthesitis
   • Refer to rheumatology if HLA-B27 positive or systemic features present

3. Patient presents with peripheral arthritis

   • Order HLA-B27 if pattern suggests spondyloarthritis (asymmetric, lower extremity, enthesitis)
   • Do NOT order with RF/anti-CCP unless features suggest overlap syndrome

The test is most valuable when pretest probability is intermediate (20-80%) based on clinical features—this is where it meaningfully changes diagnostic probability 5. In very high or very low pretest probability scenarios, the test adds limited information.